Trace Launches With $101m To Pursue ALS Drug Based On Genomic Insights

Trace Neuroscience emerged from an effort to create a new start-up using genomic insights to discover and develop treatments for amyotrophic lateral sclerosis (ALS). The company’s founders focused on the UNC13A protein, improper production of which drives synaptic dysfunction and disrupted neuronal signaling in nearly all ALS patients. Now, Trace has come out of stealth mode with $101m in series A venture capital to test its drug in patients.